Awareness of intellectual property protection must be raised

　　With its own rise, china's pharmaceutical companies protect independent intellectual property rights have been put on the agenda.　　Data show that as of 2014, Hengrui had 209 patent applications for inventions in China, of which 78 were authorized, and 100 PCT patent applications, including 81 in major countries such as the United States Hengrui Pharmaceutical's Irisibu won the China Patent Gold Award, received the national 1.1 class of chemical drugs new drug certificate; This series of innovative pharmaceutical achievements make Hengrui Pharmaceuticals stand at the forefront of China's innovative pharmaceutical companies However, with the rise of fame, low-key Hengrui Pharmaceuticals has been involved in legal battles, trouble.　　This incident, so that Hengrui pain determination to enhance the protection the level of independent intellectual property rights Hengrui is at the forefront of China's innovative pharmaceutical companies, and its experience, the future of China's pharmaceutical enterprises will also encounter Innovation is the most core competitiveness of enterprises, intellectual property protection is a strong guarantee of innovation On the road of the rise of domestic pharmaceutical enterprises, it will certainly face more and more patent wars, and domestic pharmaceutical enterprises must raise their awareness of protecting independent intellectual property rights and adapt to international competition laws in accordance with the law How to enhance the protection of independent intellectual property rights of Chinese pharmaceutical enterprises must be on the agenda.　　Previously, China's pharmaceutical innovation is very backward, China's pharmaceutical industry as a whole on the lack of awareness of intellectual property rights, they have neither maintaintheir legitimate rights and interests, leading to their own innovative drugs lack of timely intellectual property protection, and even let competitors seize their own results, some pharmaceutical enterprises infringement, not even timely detection, not enough attention, some neglect litigation, negative litigation The enterprise itself is damaged, lack of attention, affecting the long-term development of the enterprise.　　Visionary industry insiders believe that the pharmaceutical industry is very dependent on intellectual property rights, the core competitiveness is the competition of intellectual property rights Aspiring to fight in the pharmaceutical industry for a long time, and ready to go to the mainstream drug market a high and low enterprises must put intellectual property rights at a strategic height, and in order to promote the transformation and upgrading of enterprises themselves and long-term development.　　Pharmaceutical enterprises should prepare pharmaceutical enterprises intellectual property strategic plan, intellectual property development to today, its focus is no longer based on intellectual property protection, but more into a strategic resource In the face of fierce international market competition, the traditional pursuit of the maximum number of patents and neglect the quality of patent applications, as well as through infringement litigation to protect the exclusive rights of the after-the-fact remedy model, can no longer adapt to the future development of Chinese pharmaceutical enterprises Due to the wide variety of medicines, the types of intellectual property applied to each particular variety vary, and the different types of intellectual property applied to the different stages of the same variety (product life cycle) Therefore, the intellectual property strategy of pharmaceutical enterprises must be well planned, must be closely integrated with the existing product structure of enterprises and the planning of future products, the comprehensive application of various intellectual property protection methods in order to bring the best benefits to enterprises.　　In order to improve the level of intellectual property rights of pharmaceutical enterprises, we should first increase the allocation of intellectual property talents of pharmaceutical enterprises At present, many pharmaceutical enterprises do not have sufficient intellectual property personnel, the serious shortage of professionalpersons, which not only leads to the pharmaceutical enterprise planning is not strong, but also lead to scientific and technological achievements of research and development, lack of innovation The initiative of the market and the usefulness of patents are mainly promoted through specialized personnel, if the lack of intellectual property talent, will affect the various stages of the IP strategy For example, patent search, there must be proficient in pharmaceutical patents on the basic patents, subordinate patents to make a series of comprehensive search in the first place, if not clear investment in research and development, this industry is extremely dangerous, may lose hundreds of millions of dollars of funds.　　In addition, it is also very important to improve the level of intellectual property research and development achievements of pharmaceutical enterprises, although China's innovative drug research and development has made some progress, imitation innovation occupies the mainstream of China's pharmaceutical enterprises, compared with multinational pharmaceutical enterprises, there is still a considerable gap China's pharmaceutical enterprises should strive to improve the independent ability and composition of innovation in imitation, through scientific and technological innovation, and continuously improve the level of independent intellectual property rights of pharmaceutical enterprises.